SK282437B6 - Tepelne stála kryštalická modifikácia N-metyl-N-[(1S)-1-fenyl- 2-((3S)-3-hydroxypyrolidin-1-yl)etyl]-2,2- difenylacetamidhydrochloridu a spôsob jej prípravy - Google Patents

Tepelne stála kryštalická modifikácia N-metyl-N-[(1S)-1-fenyl- 2-((3S)-3-hydroxypyrolidin-1-yl)etyl]-2,2- difenylacetamidhydrochloridu a spôsob jej prípravy Download PDF

Info

Publication number
SK282437B6
SK282437B6 SK1089-96A SK108996A SK282437B6 SK 282437 B6 SK282437 B6 SK 282437B6 SK 108996 A SK108996 A SK 108996A SK 282437 B6 SK282437 B6 SK 282437B6
Authority
SK
Slovakia
Prior art keywords
hydroxypyrrolidin
phenyl
ethyl
methyl
solvent
Prior art date
Application number
SK1089-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK108996A3 (en
Inventor
Inge Stein
Holger Beeres
Klaus Beschmann
Steffen Neuenfeld
Andrew Barber
Original Assignee
Merck Patent Gesellschaft Mit Beschr�Nkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gesellschaft Mit Beschr�Nkter Haftung filed Critical Merck Patent Gesellschaft Mit Beschr�Nkter Haftung
Publication of SK108996A3 publication Critical patent/SK108996A3/sk
Publication of SK282437B6 publication Critical patent/SK282437B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SK1089-96A 1995-08-26 1996-08-22 Tepelne stála kryštalická modifikácia N-metyl-N-[(1S)-1-fenyl- 2-((3S)-3-hydroxypyrolidin-1-yl)etyl]-2,2- difenylacetamidhydrochloridu a spôsob jej prípravy SK282437B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19531464A DE19531464A1 (de) 1995-08-26 1995-08-26 N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid

Publications (2)

Publication Number Publication Date
SK108996A3 SK108996A3 (en) 1997-06-04
SK282437B6 true SK282437B6 (sk) 2002-02-05

Family

ID=7770485

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1089-96A SK282437B6 (sk) 1995-08-26 1996-08-22 Tepelne stála kryštalická modifikácia N-metyl-N-[(1S)-1-fenyl- 2-((3S)-3-hydroxypyrolidin-1-yl)etyl]-2,2- difenylacetamidhydrochloridu a spôsob jej prípravy

Country Status (25)

Country Link
US (1) US6060504A (no)
EP (1) EP0761650B1 (no)
JP (3) JP5023273B2 (no)
KR (1) KR100436254B1 (no)
CN (1) CN1081631C (no)
AR (1) AR004679A1 (no)
AT (1) ATE207895T1 (no)
AU (1) AU716615B2 (no)
BR (1) BR9603540A (no)
CA (1) CA2184049C (no)
CZ (1) CZ287783B6 (no)
DE (2) DE19531464A1 (no)
DK (1) DK0761650T3 (no)
ES (1) ES2165948T3 (no)
HU (1) HU226667B1 (no)
MX (1) MX9603606A (no)
NO (1) NO307048B1 (no)
PL (1) PL187691B1 (no)
PT (1) PT761650E (no)
RU (1) RU2174976C2 (no)
SI (1) SI0761650T1 (no)
SK (1) SK282437B6 (no)
TW (1) TW513407B (no)
UA (1) UA41978C2 (no)
ZA (1) ZA967200B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1828399A (en) * 1997-12-22 1999-07-12 Alza Corporation Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
JP2005531557A (ja) * 2002-05-17 2005-10-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 選択的オピエート受容体モジュレーターとして効果的な化合物の使用
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
WO2005046687A1 (en) * 2003-10-30 2005-05-26 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
EP2636407A3 (en) 2007-03-30 2013-11-06 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
EP2284987B1 (en) * 2009-08-12 2019-02-06 Braun GmbH Method and device for adjusting the frequency of a drive current of an electric motor
WO2011136905A2 (en) * 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
CA3047325A1 (en) * 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Solid pharmaceutical formulations of asimadoline
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide

Also Published As

Publication number Publication date
KR100436254B1 (ko) 2005-01-25
JP2012246321A (ja) 2012-12-13
DE19531464A1 (de) 1997-02-27
SI0761650T1 (en) 2002-04-30
AU716615B2 (en) 2000-03-02
HUP9602346A3 (en) 1998-01-28
JP2009046501A (ja) 2009-03-05
RU2174976C2 (ru) 2001-10-20
PL187691B1 (pl) 2004-09-30
AU6214996A (en) 1997-03-06
TW513407B (en) 2002-12-11
PT761650E (pt) 2002-04-29
EP0761650A1 (de) 1997-03-12
AR004679A1 (es) 1999-03-10
US6060504A (en) 2000-05-09
CA2184049A1 (en) 1997-02-27
CZ243496A3 (en) 1997-03-12
NO963526D0 (no) 1996-08-23
SK108996A3 (en) 1997-06-04
DE59608050D1 (de) 2001-12-06
EP0761650B1 (de) 2001-10-31
DK0761650T3 (da) 2002-02-18
CN1151986A (zh) 1997-06-18
ZA967200B (en) 1997-03-03
JP5023273B2 (ja) 2012-09-12
CZ287783B6 (en) 2001-02-14
ES2165948T3 (es) 2002-04-01
MX9603606A (es) 1997-03-29
CA2184049C (en) 2007-10-02
KR970010744A (ko) 1997-03-27
HU9602346D0 (en) 1996-10-28
ATE207895T1 (de) 2001-11-15
HUP9602346A2 (en) 1997-09-29
CN1081631C (zh) 2002-03-27
NO307048B1 (no) 2000-01-31
HU226667B1 (en) 2009-06-29
BR9603540A (pt) 1998-05-12
NO963526L (no) 1997-02-27
PL315799A1 (en) 1997-03-03
UA41978C2 (uk) 2001-10-15
JPH09110830A (ja) 1997-04-28

Similar Documents

Publication Publication Date Title
JP2012246321A (ja) Ｎ−メチル−ｎ−［（１ｓ）−１−フェニル−２−｛（３ｓ）−３−ヒドロキシピロリジン−１−イル｝エチル］−２，２−ジフェニルアセトアミド
JP5308056B2 (ja) 炎症性腹部疾患のためのカッパ−アヘン製剤作働薬
AU653902B2 (en) 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1- carboxamide as an analgesic and anti-inflammatory agent
JP2010520176A (ja) ５−（２，４−ジヒドロキシ−５−イソプロピル−フェニル）−４−（４−モルホリン−４−イルメチル−フェニル）−イソオキサゾール−３−カルボン酸エチルアミドの酸付加塩、水和物および多形、ならびにこれらの形態を含む製剤
HU193719B (en) Process for producing antiarrithmic aryloxy-6-/aminoalkyl/-1-pirrolidine- and piperidine-carboxylic acids
JPS6219577A (ja) 新規なベンジルピペラジン誘導体および該化合物を有効成分とする医薬組成物
NO139733B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive derivater av metylamin
JPH02237928A (ja) 置換ベンズアミドより成る胃の自動運動性増進用薬剤
BRPI0611096A2 (pt) (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)a mino]-1,3-tiazol-4(5h)-ona
CA2153050C (en) Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide
CN115850289B (zh) 一种新型普拉洛芬衍生物及其药物组合物和用途
LT3598B (en) Tetrahydroisoquinolinylcarbamates of 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo£2,3-b|indole
JPS6117832B2 (no)
CN114349665A (zh) 二甲双胍焦谷氨酸晶体及其制备方法与应用
RU2045268C1 (ru) Противогистаминное и антиаллергическое средство и способ приготовления глутамината хинуклидил-3-дифенилкарбинола в виде раствора для инъекций
NO159587B (no) Fremgangsm te for fremstilling av 2-(parasubstituersy)-2-alkylpropionsyrederivater.
EP0454459A2 (en) Sulfonylalkanoic acid amide derivatives

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20140822